BY ANJA HAUGE
-
Lundbeck upgrades its full-year guidance
This relates to development assumptions for both income and operating revenue.
-
Bavarian Nordic’s valuable priority review voucher for US healthcare system may be sold this year
The business has actually formerly specified that the coupon might have a worth of as much as USD 350m.
-
Novo Nordisk seeks approval for insulin drug in Japan
The item concerned is Icosema and is accepted for usage when a week.
-
After Danish factory closure: Xellia Pharmaceuticals will “definitely prefer” production in Europe
According to Sophie Løhde, Denmark’s federal government has “a solid concentrate on safeguarding the supply of anti-biotics”. Nonetheless, the Preacher of Health …
-
Side effects from Valneva’s chikungunya vaccine could make “noise” for Bavarian Nordic
In the short-term, French Valneva’s difficulties can affect the assumption of chikungunya vaccinations. However Bavarian Nordic anticipates the circumstance to finish in the …
-
Challenged by competitor: Novo Nordisk loses obesity and insulin market share
Novo Nordisk’s share of the excessive weight market goes down practically 17 portion factors, partially as a result of press from a significant rival.
-
Novo Nordisk’s rare disease business gained momentum in Q1
The progression totals up to 3%.
-
ALK aims to triple its sales force in the US
The emphasis gets on increasing making use of allergic reaction drug for youngsters, the chief executive officer informs MedWatch.
-
Authorities investigate safety of Valneva’s chikungunya vaccine
This complies with 15 instances of severe adverse effects.
-
Novartis to buy US biotech in billion-dollar deal
Swiss Novartis gets on a procurement spree, states the firm, which is acquiring a United States biotech firm for USD 1.7 bn.
